We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+23.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.4B
AUM Growth
-$5.58B
(-25%)
Cap. Flow
-$3.87B
Cap. Flow
% of AUM
-23.65%
Top 10 Holdings %
Top 10 Hldgs %
18.07%
Holding
3,458
New
283
Increased
974
Reduced
1,077
Closed
907
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$97.1M |
| 2 |
iShares Core S&P Small-Cap ETF
IJR
|
+$76.6M |
| 3 |
Lowe's Companies
LOW
|
+$75.4M |
| 4 |
Monster Beverage
MNST
|
+$64.6M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$63.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$114M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$109M |
| 3 |
Trane Technologies
TT
|
+$106M |
| 4 |
Microsoft
MSFT
|
+$104M |
| 5 |
Mastercard
MA
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.03% |
| 2 | Healthcare | 13.89% |
| 3 | Financials | 11.27% |
| 4 | Consumer Discretionary | 8.92% |
| 5 | Industrials | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Charles River Laboratories
CRL
$11.3B
| $190K | ﹤0.01% |
1,095
-111
| -9% | -$17.7K |
|
1027
Infosys
INFY
$51B
| $190K | ﹤0.01% |
19,767
+5,035
| +34% | +$45K |
|
1028
Novavax
NVAX
$1.21B
| $190K | ﹤0.01% |
+2,290
| New | +$87.6K |
|
1029
Morningstar
MORN
$7.55B
| $189K | ﹤0.01% |
1,343
-742
| -36% | -$105K |
|
|
DOCU
1030
DocuSign
DOCU
$11.1B
| $187K | ﹤0.01% |
1,094
-39,274
| -97% | -$4.95M |
|
|
SRNE
1031
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $184K | ﹤0.01% |
29,335
+200
| +0.7% | +$766 |
|
1032
Medifast
MED
$107M
| $183K | ﹤0.01% |
1,325
-965
| -42% | -$88.6K |
|
1033
Invesco Dorsey Wright Industrials Momentum ETF
PRN
$382M
| $183K | ﹤0.01% |
2,686
| – | – |
|
1034
W.R. Berkley
WRB
$28.1B
| $183K | ﹤0.01% |
7,229
-2,160
| -23% | -$53K |
|
1035
Vale
VALE
$62.3B
| $182K | ﹤0.01% |
17,814
+125
| +0.7% | +$1.14K |
|
1036
Broadridge
BR
$18.4B
| $181K | ﹤0.01% |
1,444
+95
| +7% | +$11K |
|
1037
AB InBev
BUD
$164B
| $180K | ﹤0.01% |
3,670
-224
| -6% | -$10.5K |
|
1038
eHealth
EHTH
$41.9M
| $180K | ﹤0.01% |
1,840
-1,263
| -41% | -$147K |
|
1039
Helios Technologies
HLIO
$2.47B
| $180K | ﹤0.01% |
4,835
+2,530
| +110% | +$86.3K |
|
1040
Woodward
WWD
$23B
| $180K | ﹤0.01% |
2,331
+2,294
| +6,200% | +$150K |
|
1041
Okta
OKTA
$23.8B
| $178K | ﹤0.01% |
893
+383
| +75% | +$65K |
|
|
LOV
1042
DELISTED
Spark Networks SE American Depositary Shares
LOV
| $174K | ﹤0.01% |
52,889
| – | – |
|
1043
Alamo Group
ALG
$1.91B
| $171K | ﹤0.01% |
1,674
-47
| -3% | -$4.51K |
|
1044
SouthState Bank Corp
SSB
$10.3B
| $171K | ﹤0.01% |
3,590
+30
| +0.8% | +$1.57K |
|
1045
Unum
UNM
$13.4B
| $171K | ﹤0.01% |
10,376
+7,070
| +214% | +$112K |
|
|
NATI
1046
DELISTED
National Instruments Corp
NATI
| $170K | ﹤0.01% |
4,404
-39
| -0.9% | -$1.47K |
|
1047
Travel + Leisure Co
TNL
$4.76B
| $169K | ﹤0.01% |
6,032
-2,995
| -33% | -$81.1K |
|
1048
ProShares Short S&P500
SH
$928M
| $168K | ﹤0.01% |
1,898
+50
| +3% | +$4.8K |
|
1049
Western Union
WU
$2.53B
| $168K | ﹤0.01% |
7,822
-33,345
| -81% | -$677K |
|
1050
iShares China Large-Cap ETF
FXI
$4.32B
| $167K | ﹤0.01% |
4,249
-1,426
| -25% | -$55.6K |
|
Similar funds
EWA
MIC
P
OSAM
CB
EIM
SC
Glenmede Trust's Q2 2020 Portfolio in Review
As of Q2 2020, Glenmede Trust held 3,458 positions worth $16.4B, down 25% from $21.9B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Glenmede Trust withdrew a net $3.87B in Q2 2020, closing 907 positions and reducing 1,077 holdings. Its most notable exit was Raytheon Company, an estimated $66.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Glenmede Trust opened a new position in Carrier Global worth $21.3M.
- Glenmede Trust's largest Q2 2020 buy was Carrier Global: 960,042 shares worth $21.3M.
- Glenmede Trust added most to State Street SPDR S&P 500 ETF Trust in Q2 2020, an estimated $97.1M increase.
- Glenmede Trust's biggest Q2 2020 reduction was Accenture, cutting an estimated $114M.
- Glenmede Trust fully exited Raytheon Company in Q2 2020, selling an estimated $66.5M.
- Glenmede Trust's ten largest holdings make up 18% of its $16.4B portfolio in Q2 2020.
- Glenmede Trust opened 283 new positions and closed 907 in Q2 2020.
- Glenmede Trust's portfolio value fell 25% quarter-over-quarter to $16.4B.
Based on Glenmede Trust's 13F filing for Q2 2020, filed 14 Aug 2020.